Every earnings call for LALPATHLAB — management tone, guidance, KPIs and promise tracking, quarter by quarter.
LALPATHLAB · 6 transcripts · Healthcare · latest Q4 FY26Dr. Lal Path Labs Ltd. has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue FY26 ₹2,763 cr (+12% YoY); EBITDA FY26 ₹752 cr (+8% YoY); EBITDA Margin FY26 27.2%. Revenue for Q4 FY26 grew 16.6% YoY to ₹703 crores.
Read full transcript & analysisRevenue ₹660 cr (+11% YoY); EBITDA (Pre-Exceptional) ₹179 cr (+16% YoY); EBITDA Margin (Pre-Exceptional) 27.2%. Revenue for Q3 FY26 stood at ₹660 crore, representing a 10.6% YoY growth.
Read full transcript & analysisRevenue ₹731 cr (+11% YoY); EBITDA Margin 30.7%; PAT ₹152 cr (+16% YoY). Revenue for Q2 FY26 grew 10.7% YoY to ₹731 crore, with H1 revenue reaching ₹1,400 crore (+11% YoY).
Read full transcript & analysisRevenue ₹670 cr (+11% YoY); EBITDA Margin 28.7%; PAT ₹134 cr (+24% YoY). Revenue grew 11.3% YoY to ₹670 crore, driven by volume momentum and favorable test mix.
Read full transcript & analysisRevenue ₹603 cr (+10% YoY); EBITDA Margin 28.1%; PAT ₹156 cr (+81% YoY). Revenue for Q4 FY25 reached ₹603 crore, representing a 10.5% YoY growth.
Read full transcript & analysisRevenue ₹597 cr (+11% YoY); EBITDA ₹154 cr (+10% YoY); EBITDA Margin 25.8%. Revenue grew 10.7% YoY to ₹597 crore, driven by volume and mix improvement without price increases.
Read full transcript & analysis